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Abstract : Accumulating evidence from animal studies shows that the administration 
of mesenchymal stem cells （MSCs） from adult bone marrow ameliorates tissue 
damage after ischemic injury.  In the present study we investigated the efcacy of 
MSC implantation into a hindlimb ischemia model over a short-term period to 
elucidate the effects conferred within the early phase after treatment.  MSCs from 
rats expressing green uorescence protein （GFP） were injected into rat ischemic 
limbs.  Laser Doppler perfusion imaging revealed signicantly higher blood perfu-
sion recovery in the MSC group than in the control group on days 3 and 7 after 
the treatment.  The capillary / muscle ber ratio in ischemic muscle was also sig-
nicantly higher in the MSC group than in the controls in a histological study.  In 
spite of these benets, we found no evident engraftment of the GFP-positive cells, 
and instead, the MSC treatment induced a proliferation of resident stromal cells 
in the perivascular area of the ischemic muscle, some of which produced vascular 
endothelial growth factor.  The present study suggested that MSC therapy promotes 
neovascularization even in the early phase, both directly through endothelial prolif-
eration and indirectly through activation of the resident stromal cells.
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Introduction
　Chronic critical limb ischemia （CLI） is the most severe manifestation of peripheral artery 
disease 1，2）.  CLI is a sometimes fatal condition that profoundly diminishes quality of life 
and global function.  Therapeutic angiogenesis with bone marrow mononuclear cells was 
developed as a less invasive intervention for patients severely compromised by CLI 3）, aimed 
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at improving perfusion to the ischemic vascular beds by inducing the formation of new blood 
vessels from preexisting vessels.  However, recent studies indicated that this bone marrow-
based transplantation therapy fails to confer sufficient effects on limb salvage in atherosclerotic 
peripheral artery disease 4，5）, and a new cell therapy using other cell types that will hopefully 
prove more efficacious is expected in the near future.  
　Mesenchymal stem cells （MSCs） from adult bone marrow possess attractive properties for 
use in safe and effective cardiovascular cell therapies 6）.  MSCs can be easily isolated from 
bone marrow and expanded in culture systems, and they express a number of pro-angiogenic 
cytokines such as vascular endothelial growth factor （VEGF）, as well as proteins that modulate 
endothelial cell migration 7，8）.  Our group previously examined an MSC culture system to confirm 
the angiogenic and endothelial protective effects of expressed cell factors 7，9）.  A co-culture with 
human MSCs induced prominent capillary network formation in our in-vitro angiogenesis assay 9）.  
　Previous studies have demonstrated the mid- to long-term benefits of MSC implantation on 
limb perfusion in a rodent limb ischemia model 10，11）, but the effects conferred within the early 
phase after treatment remain to be fully understood.  In this study we investigated the efficacy 
of MSC therapy in the short time frame just after implantation.   
Methods
Isolation and culture of MSCs from GFP-rat bone marrow
　We isolated and cultured MSCs from the bone marrow of adult transgenic Sprague-
Dawley rats ubiquitously expressing enhanced green fluorescence protein （GFP）, as previously 
described 12）.  In brief, mononuclear cells were purified from GFP-rat bone marrow by density 
centrifugation and resuspended in a complete culture medium （CCM） consisting of alpha-MEM 
（Life Technologies, Carlsbad, CA） with 20％ fetal calf serum （Atlantic Biologicals, Norcross, 
GA）, 100 U / ml penicillin, 100 µg / ml streptomycin, and 1 mM L-glutamine.  The cells were 
plated in 20 ml of medium in a 150-cm2 culture dish and incubated in a humidified incubator 
with 95％ air and 5％ CO2 at 37℃ .  After 24 h, the non-adherent cells were removed and the 
primary adherent cells were cultured and propagated.  
　For cell implantation, the MSCs （passages 5 to 7） were plated in CCM with a change of 
medium every 4 days until the cultures reached 70～ 80％ confluence.  The cells thus prepared 
were harvested and injected into rat ischemic limbs.
Rat hindlimb ischemia model and cell implantation
　This study was performed in accordance with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health.  The Animal Care and Use 
Committee of Showa University approved the experimental protocol.  
　Hindlimb ischemia was induced in 8-week-old male Wister rats by ligating the right femoral 
arteries under anesthesia.  The distal portion of the saphenous artery and all of the side 
branches were ligated, along with the veins.  The left hindlimb was kept intact and used as a 
non-ischemic limb.  After the operation, the rats were injected with either MSCs （5×105 cells, 
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n＝11） or vehicle （control, n＝11） into the ischemic adductor muscle at four sites.  
　Blood perfusion was assessed by laser Doppler perfusion imaging （LDPI） （Omega Zone, 
Muromachi, Tokyo, Japan） on days 3 and 7 after the operation.  The blood flow distribution of 
the limb was mapped out as a color-coded image of intensity directly proportional to the blood 
flow perfusion.  The LDPI index was used to calculate the blood perfusion ratio of the ischemic 
and non-ischemic hindlimbs.  Tissue samples were obtained from rat ischemic adductor muscles 
at 7 days after surgery for immunohistochemistry.  
Quantification of capillary vessels and proliferating cells
　Immunohistochemistry for CD31 and Ki67 was performed to detect capillary vessels and 
proliferating cells, respectively, in rat ischemic limbs as previously described 9）.  The sections 
（5 µm） were deparaffinized and subjected to a 3-step staining procedure using streptavidin-
biotin complex with horseradish peroxidase.  Horseradish peroxidase activity was visualized with 
diaminobenzidine substrate, and the sections were faintly counterstained with hematoxylin.  The 
primary antibodies used were raised against CD31 （1:100 dilution, DAKO, Carpinteria, CA） and 
Ki67 （1:100 dilution, Abcam, Cambridge, UK） proteins.  
　Three fields from each tissue section （n＝6） were randomly selected and CD31-positive cells 
were counted in each field.  To avoid over- or underestimating the capillaries as a consequence 
of myocyte atrophy or interstitial edema, the capillary number adjusted per muscle fiber was 
used to compare differences in capillary density.  The proliferating cell index was defined as the 
ratio of Ki67-positive cells to the total number of cells in each perivascular interstitial area.
Immunouorescence 
　Immunofluorescence was performed as previously described 7）.  Tissue sections were 
incubated with anti-GFP （1:400, Life Technologies） and anti-VEGF （1:100 dilution, Santa Cruz 
Biotechnology, Santa Cruz, CA）, and then with secondary antibodies conjugated to Alexa 488 
（1:1000）.  Slides were mounted in Vectashield containing 4’, 6-diamidino-2-phenylindole （Vector 
Labs）.
Data analysis
　All data were expressed as mean ±SD.  Student’s t-test was used to compare differences 
between groups.  Probability values of ＜0.05 were considered significant.
Results
Enhanced neovascularization in rat ischemic limbs by MSC implantation
　Bone marrow MSCs from GFP rats （5×10 5 cells） were injected into rat ischemic limbs, and 
blood perfusion recovery of the ischemic hindlimb was evaluated by LDPI.  Hindlimb ischemia 
was markedly improved in the MSC group （Fig. 1）, with the quantitative analysis of LDPI 
findings revealing significantly higher perfusion recovery compared to rats in the control group 
on days 3 and 7 after treatment.  
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Fig. 1.  Blood flow recovery in rat ischemic muscle. Upper, Representative images of laser Doppler blood 
flow in the control and MSC groups. Blood perfusion signals of the ischemic limb were higher 
in the MSC-treated limb compared than in the controls on days 3 and 7.  Lower, The ischemic /
normal laser Doppler blood flow ratio was significantly higher in the MSC group than in the 
control group （Con） in the quantitative analysis. n＝11 in each group ; #, P＜ 0.001 on day 3 ; ＊, 
P＜ 0.05 on day 7. LDPI, laser Doppler perfusion imaging.
Fig. 2.  Capillary density in rat ischemic muscle. Upper, Immunohisto-
chemical staining for CD31 in muscle sections on day 7 after the 
treatment. Lower, The capillary / muscle fiber ratio was significantly 
higher in the MSC group than in the control group （Con） by 
quan tit a tive analysis. Bar＝200 µm. n＝6 in each group ; ＊, P＜0.05.
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　In the histological study, more capillary vessels were detected in the ischemic muscle treated 
with MSCs than in the control group on day 7 after the implantation （Fig. 2）.  The capillary /
muscle fiber ratio in ischemic muscle was also significantly higher in the MSC group than in 
controls.
　Thus, local MSC administration into the ischemic limb significantly enhanced neovascularization 
even in the early phase after implantation.  
MSC engraftment after the implantation 
　Immunohistochemical assessment of the extent of MSC engraftment revealed no MSCs （GFP 
signal） in the ischemic muscles of MSC-treated rats at 1 week after implantation （Fig. 3）.  In 
an earlier study, we also found that MSCs exerted favorable cardiac effects after myocardial 
infarction without long-term engraftment or differentiation7）.  The benefits demonstrated in that 
study were attributable to transitory paracrine effects or secreted factors following the MSC 
administration.  In the present study we similarly found that MSCs promoted neovascularization 
in ischemic limb muscle without persistent engraftment.
Stromal cell proliferation in muscle
　In addition to enhanced angiogenesis, we also observed an increased number of Ki67-positive 
cells in the perivascular interstitial area of the ischemic muscle treated implanted with MSCs 
（Fig. 4）, and quantitative analysis indicated a significantly higher ratio of proliferating stromal 
cells in the MSC group than in controls.  Interestingly, while the MSC implantation induced 
stromal cell proliferation, fibrosis of the hindlimb muscle was less extensive after ischemic injury 
and seemed not to differ between the groups on day 7 （data not shown）.  
　The absence of GFP-positive cells indicated that the proliferating stromal cells were derived 
Fig. 3.  No engraftment of MSCs from GFP rats in ischemic muscle. Left, Microscopic image 
of GFP-positive MSCs in the culture system. Right, Representative sections showing 
immunofluorescence for GFP （green）. Blue fluorescence indicates DAPI nuclear staining. 
No GFP-positive cells were engrafted into the ischemic muscle. GFP, green fluorescence 
protein ; DAPI, 4’,6-diamidino-2-phenylindole.
Sayaka USUI, et al126
from a source other than the injected MSCs.  As it turned out, the stromal cells in the 
perivascular interstitial area expressed VEGF （Fig. 5）.
　Together, the findings suggested that the enhanced neovascularization by MSC implantation 
was at least partly attributable to the activation of resident stromal cells with angiogenic 
potential.
Discussion  
　MSCs from bone marrow significantly promoted neovascularization in rat ischemic limbs in 
the early phase after implantation without cell engraftment, and the effect could be attributed 
to paracrine action.  We previously reported improved cardiac function in the absence of long-
Fig. 4.  Proliferating stromal cells in ischemic muscle. Upper, 
Immunohistochemical staining for Ki67, a cell proliferation 
marker, in muscle sections on day 7 after the treatment. Ki67-
positive cells were detected in the perivascular interstitial area. 
Lower, By quantitative analysis, the ratio between the number 
of Ki67-positive cells and the total number of cells in the 
perivascular interstitial area was significantly higher in the MSC 
group than in the control group （Con）. Arrows indicate Ki67-
positive cells. Bar＝20 µm. n＝6 in each group ; ＊, P＜ 0.05. 
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term engraftment with systemic administration of human MSCs into immunodeficient mice 
with myocardial infarction7）.  In that study, the MSC-conditioned medium from the same donor 
protected both cultured murine cardiomyocytes and human umbilical vein endothelial cells from 
cell death during hypoxia.  Consistent with the present results, the MSC-conferred benefits for 
cardiac repair also appeared to derive from a transitory paracrine action or from factors secreted 
by the cells.  
　Factors secreted from MSCs alter the growth, differentiation, survival, and / or function of 
endogenous resident cells even though they derive from a disparate tissue source13，14）.  Several 
studies from other groups support the paracrine hypothesis for MSC-mediated angiogenesis 
and cardioprotection10，11，15，16）.  MSCs are a robust source of angiogenic factors7，8，10）, and in 
experiments comparing cultured human MSCs with hematopoietic stem cells, the former 
expressed higher mRNA levels for pro-angiogenic factors such as VEGF and adrenomedullin7）, 
while conditioned medium from the MSCs rescued human umbilical vein endothelial cells from 
cell death during hypoxia exposure.  We have also observed an in-vivo vasculoprotective effect of 
conditioned medium from MSCs in a mouse model of myocardial infarction17）.  Implanted MSCs 
apparently protect endothelial cells and induce their proliferation in ischemic tissue via secretion 
of several angiogenic factors.
　Another important finding in the present study was the enhanced proliferation of stromal 
cells in the perivascular area of the MSC treated-ischemic limbs.  MSCs secrete basic fibroblast 
growth factor （bFGF） as well as VEGF 7，9）, and bFGF released from MSCs promotes 
wound healing via stromal cell migration and proliferation18，19）.  MSCs also stimulate both 
the proliferation and neurogenesis of endogenous neural progenitor cells in the hippocampus 
after intracranial administration 20）.  The administration of peripheral blood mononuclear cells 
also induced the activation and marked proliferation of myoblasts in ischemic skeletal muscle, 
resulting in coordinated muscle regeneration and enhanced neovascularization21）.  We therefore 
assumed that stem / progenitor cells from one tissue could be used to influence the in situ 
Fig. 5.  Vascular endothelial growth factor （VEGF） expression of perivascular stromal cells in rat ischemic 
muscle. Green fluorescence indicates VEGF. Blue fluorescence indicates DAPI nuclear staining. 
Microscopic observation revealed that some of the perivascular stromal cells produced VEGF. Bar＝
20 µm, DAPI, 4’,6-diamidino-2-phenylindole.
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activation of not only endothelial cells, but also the resident primitive cells from a different adult 
tissue.  
　Some of the stromal cells in ischemic muscle produced VEGF in the present study.  In 
tumor biology, tumor angiogenesis is augmented by the induction of VEGF in perivascular 
stromal cells22）, thus the stromal cells in skeletal muscle are likely to be one of the resident 
cells with angiogenic potential.  We can thus hypothesize that the MSCs not only promote the 
endothelial proliferation directly, but also induce neovascularization indirectly via the activation 
of perivascular stromal cells in a paracrine fashion.  Our previous study likely supports this 
hypothesis, in that MSC therapy significantly increased VEGF levels in remote areas wholly 
devoid of MSCs in a porcine myocardial infarction model 9）.  In these experiments, the MSC-
treated heart contained clusters of resident interstitial cells positive for phospho-STAT3, a 
regulator of VEGF production.  However, stromal cell populations are heterogeneous, and VEGF 
expression was apparently absent in some of the single stromal cells.  Further studies will be 
necessary to explore the stromal cell subpopulation responsible for angiogenesis in endogenous 
reparative processes.
　In conclusion, a salutary effect of the MSC implantation could be demonstrated within 3 days 
after treatment, and the efficacy was sustained without persistent cell engraftment.  The present 
study suggested that MSC therapy promotes neovascularization even in the early phase, both 
directly via endothelial proliferation and indirectly via activation of the resident stromal cells in a 
paracrine fashion by factors secreted from the MSCs.  
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